Inhibitex

It produced a measurable degree of immunity in recipients, though that immunity faded after forty weeks.30 But when the company repeated the trial with a larger number of patients and a booster dose, its results were no better than the placebo used against it, and Nabi suspended the program in 2005.31 A second vaccine attempt by a company called Inhibitex, using a formula they dubbed Veronate, aimed for what is called passive immunization—meaning that, rather than stimulating the body to make antibodies, it delivers already-formed antibodies harvested from blood donors.

SUPERBUG MARYN MCKENNA 2010

It produced a measurable degree of immunity in recipients, though that immunity faded after forty weeks.30 But when the company repeated the trial with a larger number of patients and a booster dose, its results were no better than the placebo used against it, and Nabi suspended the program in 2005.31 A second vaccine attempt by a company called Inhibitex, using a formula they dubbed Veronate, aimed for what is called passive immunization—meaning that, rather than stimulating the body to make antibodies, it delivers already-formed antibodies harvested from blood donors.

SUPERBUG MARYN MCKENNA 2010

It produced a measurable degree of immunity in recipients, though that immunity faded after forty weeks.30 But when the company repeated the trial with a larger number of patients and a booster dose, its results were no better than the placebo used against it, and Nabi suspended the program in 2005.31 A second vaccine attempt by a company called Inhibitex, using a formula they dubbed Veronate, aimed for what is called passive immunization—meaning that, rather than stimulating the body to make antibodies, it delivers already-formed antibodies harvested from blood donors.

SUPERBUG MARYN MCKENNA 2010

Bristol-Myers Squibb said it is buying hepatitis C drug developer Inhibitex for $2.5 billion, the latest deal in the business of treating the potentially fatal virus.

What's News— 2012

Most recently, Bristol agreed to acquire hepatitis C drug developer Inhibitex Inc. for about $2.5 billion.

Bristol-Myers Net Rises 76% on Lower Taxes Peter Loftus 2012

Inhibitex shares are surging today, on stronger than usual volume, after it reported financial results for the third quarter, and highlighted data from a clinical trial.

Inhibitex Shares Surge Trial, Earnings News 2011

Inhibitex said it lost $5.3 million in the third quarter, equal to its loss in the third quarter of 2010.

Inhibitex Shares Surge Trial, Earnings News 2011

Bristol-Myers is buying hepatitis C drug developer Inhibitex for about $2.5 billion, marking the latest deal in the growing business of treating the potentially fatal virus.

What's News— 2012

Over the weekend, Bristol-Myers Squibb Co. agreed to pay a high premium to acquire another player in the category, drug developer Inhibitex Inc., for about $2.5 billion.

Idenix Reports Positive Interim Data for Hepatitis C Drug Ben Fox Rubin 2012

Bristol-Myers Squibb agreed to buy hepatitis-C drug developer Inhibitex for about $2.5 billion, triggering a 140% surge in the takeover target's stock.

Stocks End Higher; Alcoa Rises Brendan Conway 2012